Table 2.
The incidence of dyspnoea and ventricular pauses by sex and treatment
| Ticagrelor | Clopidogrel | Interaction P-value |
||
|---|---|---|---|---|
| Dyspnoea | KM % (n) | KM % (n) | HR (95% CI) | |
| Women | 16.3 (389) | 9.0 (214) | 1.86 (1.58–2.20) | 0.7610 |
| Men | 14.2 (870) | 8.3 (500) | 1.81 (1.62–2.01) | |
| Ventricular pauses | % (n/N) | % (n/N) | OR (95% CI) | |
| First week | ||||
| ≥3 s | ||||
| Women | 5.2 (20/386) | 3.4 (13/381) | 1.55 (0.76–3.16) | 0.8860 |
| Men | 6.0 (64/1075) | 3.7 (39/1051) | 1.64 (1.09–2.47) | |
| ≥5 s | ||||
| Women | 1.3 (5/386) | 1.3 (5/381) | 0.99 (0.28–3.44) | 0.3408 |
| Men | 2.2 (24/1075) | 1.1 (12/1051) | 1.98 (0.98–3.97) | |
| At 30 days | ||||
| ≥3 s | ||||
| Women | 1.2 (3/249) | 1.1 (3/265) | 1.07 (0.21–5.33) | 0.8241 |
| Men | 2.4 (18/743) | 1.9 (14/747) | 1.30 (0.64–2.63) | |
| ≥5 s | ||||
| Women | 0.4 (1/249) | 0.4 (1/265) | 1.07 (0.07–17.1) | 0.8541 |
| Men | 0.9 (7/743) | 0.7 (5/747) | 1.41 (0.45–4.47) | |
CI, confidence interval; HR, hazard ratio; KM, Kaplan–Meier analysis; OR, odds ratio.